FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 10:24:23 2024-06-03 am EDT | ||
| 27.59 EUR / 27.62 EUR | +3.62% |
|
| 1 month | +2.54% | ||
| 3 months | +42.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 27.17 | +1.99% |
| 24-05-31 | 26.64 | +2.11% |
| 24-05-30 | 26.09 | +1.83% |
| 24-05-29 | 25.62 | -1.58% |
| 24-05-28 | 26.03 | -4.93% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 09:27 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD4ZQ0 |
| ISIN | DE000SD4ZQ08 |
| Date issued | 2021-03-26 |
| Strike | 7,134 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 11.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.33 € |
|---|---|
| Lowest since issue | 14.16 € |
| Spread | 0.04 € |
| Spread % | 0.15% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
